Potencial terapéutico de las chalconas en la lucha contra el dengue: análisis bibliométrico
DOI:
https://doi.org/10.17058/reci.v16i.20407Palabras clave:
Estudio Bibliométrico, Bibliometrix, Chalcona, Dengue, Aedes aegyptiResumen
Justificación y Objetivos: El dengue es una enfermedad viral transmitida por el mosquito Aedes aegypti, caracterizada por su rápida propagación e impacto global. Además del dengue, este vector también es responsable de la transmisión de los virus del Zika y el Chikunguña. Dada la limitada disponibilidad de terapias antivirales, el desarrollo de nuevos tratamientos es crucial. Los compuestos de chalcona han demostrado potencial larvicida y antiviral, lo que los convierte en candidatos prometedores en la lucha contra estas enfermedades. Este estudio busca realizar una revisión bibliográfica sobre el potencial terapéutico de las chalconas en la lucha contra el dengue mediante análisis bibliométrico. Contenido:El análisis bibliométrico se realizó utilizando la base de datos Scopus para identificar publicaciones tanto globales como nacionales. La recopilación de datos incluyó estrategias de búsqueda booleana y filtros específicos, y los documentos recuperados se analizaron mediante la herramienta Bibliometrix para evaluar las principales tendencias de investigación, las redes de colaboración y la contribución de Brasil al campo. El análisis destaca los principales dominios de investigación, las contribuciones de los autores, las afiliaciones institucionales y las tendencias de publicación por país. Mediante el análisis de publicaciones de 2006 a 2024, el estudio identifica las áreas de investigación más destacadas, los autores principales, las revistas influyentes y las contribuciones específicas de cada país. Conclusión: Los hallazgos revelan una creciente producción científica sobre las chalconas y el dengue, con estudios pioneros que subrayan su potencial antiviral. El estudio también mapea las redes de colaboración global, contribuyendo a los avances en el descubrimiento de antivirales y el control de vectores.
Descargas
Referencias
1. Kularatne AS, Dalugama C. Dengue Infection: Global Importance, Immunopathology and Management. Clin. Med. (Northfield. Il). 2022, 22 (1), 9–13. https://doi.org/10.7861/clinmed.2021-0791.
2. Almeida e Sá FH, Silva ARN, de Oliveira TJS, et al. Chalcone Identified by in Silico and in Vitro Assays Possesses High Larvicidal Activity against Aedes Aegypti. Acta Trop. 2023, 238, 106791. https://doi.org/10.1016/j.actatropica.2022.106791.
3. Wong JM, Adams LE, Durbin AP, et al. Dengue: A Growing Problem With New Interventions. Pediatrics 2022, 149 (6). https://doi.org/10.1542/peds.2021-055522.
4. Parveen S, Riaz Z, Saeed S, et al. Dengue Hemorrhagic Fever: A Growing Global Menace. J. Water Health 2023, 21 (11), 1632–1650. https://doi.org/10.2166/wh.2023.114.
5. ONU. Opas: epidemia histórica de dengue nas Américas eleva risco para crianças. 2024.
6. Elkhalifa D, Al-Hashimi I, Al Moustafa AE, Khalil A. A Comprehensive Review on the Antiviral Activities of Chalcones. J. Drug Target. 2021, 29 (4), 403–419. https://doi.org/10.1080/1061186X.2020.1853759.
7. Ouyang Y, Li J, Chen X, Fu X, Sun S, Wu Q. Chalcone Derivatives: Role in Anticancer Therapy. Biomolecules 2021, 11 (6), 894. https://doi.org/10.3390/biom11060894.
8. Cheng P, Yang L, Huang X, Wang X, Gong M. Chalcone Hybrids and Their Antimalarial Activity. Arch. Pharm. (Weinheim). 2020, 353 (4). https://doi.org/10.1002/ardp.201900350.
9. Dhaliwal JS, Moshawih S, Goh KW, et al. Pharmacotherapeutics Applications and Chemistry of Chalcone Derivatives. Molecules 2022, 27 (20), 7062. https://doi.org/10.3390/molecules27207062.
10. Gomes M, Muratov E, Pereira M, et al. Chalcone Derivatives: Promising Starting Points for Drug Design. Molecules 2017, 22 (8), 1210. https://doi.org/10.3390/molecules22081210.
11. Donthu N, Kumar S, Mukherjee D, Pandey N, Lim WM. How to Conduct a Bibliometric Analysis: An Overview and Guidelines. J. Bus. Res. 2021, 133, 285–296. https://doi.org/10.1016/j.jbusres.2021.04.070.
12. Aria, M, Cuccurullo, C. Bibliometrix : An R-Tool for Comprehensive Science Mapping Analysis. J. Informetr. 2017, 11 (4), 959–975. https://doi.org/10.1016/j.joi.2017.08.007.
13. Hariono M, Choi SB, Roslim RF, et al. Thioguanine-Based DENV-2 NS2B/NS3 Protease Inhibitors: Virtual Screening, Synthesis, Biological Evaluation and Molecular Modelling. PLoS One 2019, 14 (1), e0210869. https://doi.org/10.1371/journal.pone.0210869.
14. Heh CH, Othman R, Buckle MJC, Sharifuddin Y, Yusof R, Rahman N. A. Rational Discovery of Dengue Type 2 Non‐Competitive Inhibitors. Chem. Biol. Drug Des. 2013, 82 (1), 1–11. https://doi.org/10.1111/cbdd.12122.
15. Chee CF, Abdullah I, Buckle MJC, Rahman NA. An Efficient Synthesis of (±)-Panduratin A and (±)-Isopanduratin A, Inhibitors of Dengue-2 Viral Activity. Tetrahedron Lett. 2010, 51 (3), 495–498. https://doi.org/10.1016/j.tetlet.2009.11.030.
16. Kiat TS, Pippen R, Yusof R, Ibrahim H, Khalid N, Rahman, N. A. Inhibitory Activity of Cyclohexenyl Chalcone Derivatives and Flavonoids of Fingerroot, Boesenbergia Rotunda (L.), towards Dengue-2 Virus NS3 Protease. Bioorg. Med. Chem. Lett. 2006, 16 (12), 3337–3340. https://doi.org/10.1016/j.bmcl.2005.12.075.
17. Md-Mustafa ND, Khalid N, Gao H, et al. Transcriptome Profiling Shows Gene Regulation Patterns in a Flavonoid Pathway in Response to Exogenous Phenylalanine in Boesenbergia Rotunda Cell Culture. BMC Genomics 2014, 15 (1), 984. https://doi.org/10.1186/1471-2164-15-984.
18. Koçyiğit-Kaymakçıoğlu B, Beyhan N, Tabanca N, et al. Discovery and Structure Activity Relationships of 2-Pyrazolines Derived from Chalcones from a Pest Management Perspective. Med. Chem. Res. 2015, 24 (10), 3632–3644. https://doi.org/10.1007/s00044-015-1415-8.
19. Mottin M, Caesar LK, Brodsky D, et al. Chalcones from Angelica Keiskei (Ashitaba) Inhibit Key Zika Virus Replication Proteins. Bioorg. Chem. 2022, 120, 105649. https://doi.org/10.1016/j.bioorg.2022.105649.
20. Jeon YJ, Jung SN, Chang H, et al. Artocarpus Altilis (Parkinson) Fosberg Extracts and Geranyl Dihydrochalcone Inhibit STAT3 Activity in Prostate Cancer DU145 Cells. Phyther. Res. 2015, 29 (5), 749–756. https://doi.org/10.1002/ptr.5311.
21. Patil SA, Patil V, Patil R, Beaman K, Patil SA. Identification of Novel 5,6-Dimethoxyindan-1-One Derivatives as Antiviral Agents. Med. Chem. (Los. Angeles). 2017, 13 (8). https://doi.org/10.2174/1573406413666170330094822.
22. Patil V, Patil, SA, Patil R, Bugarin A, Beaman K, Patil SA. Exploration of (Hetero)Aryl Derived Thienylchalcones for Antiviral and Anticancer Activities. Med. Chem. (Los. Angeles). 2019, 15 (2), 150–161. https://doi.org/10.2174/1573406414666180524074648.
23. Bharathi A, Roopan SM, Rahuman AA, Rajakumar G. In Vitro Larvicidal and Antioxidant Activity of Dihydrophenanthroline-3-Carbonitriles. Biomed Res. Int. 2014, 2014, 1–8. https://doi.org/10.1155/2014/915797.
24. Santos M, Da Silva Santos F, Ferraz A, et al. Triazole-Chalcones: Lack of Antibacterial, Anti-Candida, and Anti-Dengue Virus Activities. J. Pharm. Negat. Results 2018, 9 (1), 39. https://doi.org/10.4103/jpnr.JPNR_2_18.
25. Ganji LR, Gandhi L, Musturi V, Kanyalkar MA. Design, Synthesis, and Evaluation of Different Scaffold Derivatives against NS2B-NS3 Protease of Dengue Virus. Med. Chem. Res. 2021, 30 (1), 285–301. https://doi.org/10.1007/s00044-020-02660-y.
26. Parida P, Yadav RNS, Dehury B, et al. Novel Insights into the Molecular Interaction of a Panduratin A Derivative with the Non Structural Protein (NS3) of Dengue Serotypes: A Molecular Dynamics Study. Curr. Pharm. Biotechnol. 2017, 18 (9). https://doi.org/10.2174/1389201018666171122122338.
27. Purohit P, Barik D, Agasti S, Panda M, Meher BR. Evaluation of the Inhibitory Potency of Anti-Dengue Phytocompounds against DENV-2 NS2B-NS3 Protease: Virtual Screening, ADMET Profiling and Molecular Dynamics Simulation Investigations. J. Biomol. Struct. Dyn. 2024, 42 (6), 2990–3009. https://doi.org/10.1080/07391102.2023.2212798.
28. Cao V, Sukanadi IP, Loeanurit N, et al. A Sulfonamide Chalcone Inhibited Dengue Virus with a Potential Target at the SAM-Binding Site of Viral Methyltransferase. Antiviral Res. 2023, 220, 105753. https://doi.org/10.1016/j.antiviral.2023.105753.
29. Lima WG, Andrade JT, da Silva Santos FR, et al. Antibacterial, Antifungal, and Antiviral Activities of Chalcone-Bearing Tetrahydropyranyl and 2,4-Dihydroxyl Moieties. Rev. Colomb. Ciencias Químico-Farmacéuticas 2020, 49 (1). https://doi.org/10.15446/rcciquifa.v49n1.87036.
30. Huq AKMM, Roney M, Dubey A, et al. Phenolic Compounds of Theobroma Cacao L. Show Potential against Dengue RdRp Protease Enzyme Inhibition by In-Silico Docking, DFT Study, MD Simulation and MMGBSA Calculation. PLoS One 2024, 19 (3), e0299238. https://doi.org/10.1371/journal.pone.0299238.
31. Musatat AB, Durmuş T, Atahan A. Harnessing High Potential Benzothiazole Chalcones against Dengue Virus NS5 Protein: A Multi-Faceted Theoretical Study through Molecular Docking, ADME, and DFT. Arch. Biochem. Biophys. 2024, 761, 110171. https://doi.org/10.1016/j.abb.2024.110171.
32. Ali SI, Sheikh WM, Rather MA, Venkatesalu V, Muzamil Bashir S, Nabi SU. Medicinal Plants: Treasure for Antiviral Drug Discovery. Phyther. Res. 2021, 35 (7), 3447–3483. https://doi.org/10.1002/ptr.7039.
33. Marinescu M. Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities. Antibiotics 2021, 10 (8), 1002. https://doi.org/10.3390/antibiotics10081002.
34. Poonia N, Kumar A, Kumar V, Yadav M, Lal K. Recent Progress in 1H-1,2,3-Triazoles as Potential Antifungal Agents. Curr. Top. Med. Chem. 2021, 21 (23), 2109–2133. https://doi.org/10.2174/1568026621666210913122828.
35. Melino S, Paci M. Progress for Dengue Virus Diseases. FEBS J. 2007, 274 (12), 2986–3002. https://doi.org/10.1111/j.1742-4658.2007.05831.x.
36. Ali F, Chorsiya A, Anjum V, Khasimbi S, Ali A. A Systematic Review on Phytochemicals for the Treatment of Dengue. Phyther. Res. 2021, 35 (4), 1782–1816. https://doi.org/10.1002/ptr.6917.
37. Shawon J, Akter Z, Hossen MM, et al. A. Current Landscape of Natural Products against Coronaviruses: Perspectives in COVID-19 Treatment and Anti-Viral Mechanism. Curr. Pharm. Des. 2020, 26 (41), 5241–5260. https://doi.org/10.2174/1381612826666201106093912.
38. Pereira RS, Santos FCP, Campana PRV, et al. Natural Products and Derivatives as Potential Zika Virus Inhibitors: A Comprehensive Review. Viruses 2023, 15 (5), 1211. https://doi.org/10.3390/v15051211.
39. Saha C, Naskar R, Chakraborty S. Antiviral Flavonoids: A Natural Scaffold with Prospects as Phytomedicines against SARS-CoV2. Mini-Reviews Med. Chem. 2024, 24 (1), 39–59. https://doi.org/10.2174/1389557523666230503105053.
40. Sardari S, Rafieian-Kopaei M, Malekmohammad K, Sewell RDE. Review of Phytochemical Compounds as Antiviral Agents Against Arboviruses from the Genera Flavivirus and Alphavirus. Curr. Drug Discov. Technol. 2020, 17 (4), 484–497. https://doi.org/10.2174/1570163817666200122102443.
41. Sobhia ME, Ghosh K, Singh A, et al. A Multi-Perspective Review on Dengue Research. Curr. Drug Targets 2019, 20 (15), 1550–1562. https://doi.org/10.2174/1389450120666190724145937.
42. Singh S, Sharma S, Sharma H. Naturally Occurring Herbs and Their Bioactive Metabolites: Potential Targets and Signaling Pathways of Antiviral Agents. Endocrine, Metab. Immune Disord. - Drug Targets 2023, 23 (12), 1505–1537. https://doi.org/10.2174/1871530323666230622122901.
43. Laengle S, Merigó JM, Miranda J, et al. Forty Years of the European Journal of Operational Research: A Bibliometric Overview. Eur. J. Oper. Res. 2017, 262 (3), 803–816. https://doi.org/10.1016/j.ejor.2017.04.027.
44. Chuang YT, Lin YL, Lin JY. Licochalcone A Regulates Viral IRES Activity to Inhibit Enterovirus Replication. Antiviral Res. 2024, 221, 105755. https://doi.org/10.1016/j.antiviral.2023.105755.
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2026 Danúbio Andrade Bezerra Farias, Luiz Francisco Wemmenson Gonçalves Moura, Natália do Vale Canabrava, Francisco Leandro Fernandes Sampaio, José Ítalo Magalhães de Sousa, Vânia Marilande Ceccatto, Márcia Maria Mendes Marques Duque, Maria Izabel Florindo Guedes

Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
The author must state that the paper is original (has not been published previously), not infringing any copyright or other ownership right involving third parties. Once the paper is submitted, the Journal reserves the right to make normative changes, such as spelling and grammar, in order to maintain the language standard, but respecting the author’s style. The published papers become ownership of RECI, considering that all the opinions expressed by the authors are their responsibility. Because we are an open access journal, we allow free use of articles in educational and scientific applications provided the source is cited under the Creative Commons CC-BY license.